Continued organic growth Nine-month 2024 revenue of €9.1 million (+21%)

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, recorded an excellent third quarter in 2024, with revenue of €2.6 million, representing purely organic growth (excluding change in the scope of consolidation) of 24% compared with the previous year. As a result, ninemonth revenue was €9.1 million, an increase of 21% on 2023.